All Stories

  1. La terapia immunosoppressiva nel trapianto di rene
  2. Fisiopatologia del rigetto acuto e cronico
  3. Principi di immunobiologia del trapianto ed attivazione della risposta immune
  4. I perché di una nuova rubrica sul Trapianto renale
  5. Impact of donor-specific antibodies on the outcomes of kidney graft: Pathophysiology, clinical, therapy
  6. Update on hemolytic uremic syndrome: Diagnostic and therapeutic recommendations
  7. Is it time to give up with calcineurin inhibitors in kidney transplantation?
  8. Enteric-coated mycophenolate sodium immunosuppression in renal transplant patients: efficacy and dosing
  9. Relationship Among Endothelial Response to Hyperemia, Bone Marrow-Derived Progenitor Cells, and Parathyroid Hormone in Renal Transplantation
  10. Antineoplastic effects of mammalian target of rapamycine inhibitors
  11. Renal transplant allocation criteria, desensitization strategies and immunosuppressive therapy in retransplant renal patients
  12. The Kidney, a Victim and Culprit of Autoimmune and Alloimmune Responses
  13. Everolimus and Minimization of Cyclosporine in Renal Transplantation: 24-Month Follow-Up of the EVEREST Study
  14. Long-term outcome of everolimus treatment in transplant patients
  15. Genome-wide association study identifies susceptibility loci for IgA nephropathy
  16. What is the purpose of launching the World Journal of Transplantation?
  17. Good outcomes with Cyclosporine very low exposure with Everolimus high exposure in renal transplant patients
  18. Stability Problems
  19. Everolimus With Very Low-Exposure Cyclosporine A in De Novo Kidney Transplantation: A Multicenter, Randomized, Controlled Trial
  20. High pretransplant serum levels of CXCL9 are associated with increased risk of acute rejection and graft failure in kidney graft recipients
  21. Sexual Dysfunction in Women During Dialysis and after Renal Transplantation
  22. Pretransplant Positivity for Circulating Thyroid Antibodies and Graft Survival in Patients Undergoing Kidney Transplant
  23. Post‐transplant proteinuria associated with everolimus: Definition of main features with proteomics
  24. KIDNEY GRAFT SURVIVAL RATE DON'T IMPROVE BY ERA: THE IMPACT OF FACTOR “AGE”
  25. Proteins and protein fragments in nephrotic syndrome: Clusters, specificity and mechanisms
  26. Pretransplant serum FT3 levels in kidney graft recipients are useful for identifying patients with higher risk for graft failure
  27. Efficacy and safety of enteric‐coated mycophenolate sodium in renal transplant patients with diabetes mellitus: post hoc analyses from three clinical trials
  28. Randomized Controlled Trial of FTY720 Versus MMF in De Novo Renal Transplantation
  29. Mycophenolic Acid Use in Glomerulonephritis
  30. Follow-up after renal transplantation with organs from donors after cardiac death
  31. Enteric-coated mycophenolate sodium: role in transplantation
  32. A Randomized Pilot Trial Comparing Methylprednisolone Plus a Cytotoxic Agent Versus Synthetic Adrenocorticotropic Hormone in Idiopathic Membranous Nephropathy
  33. Estimated One-Year Glomerular Filtration Rate is the Best Predictor of Long-term Graft Function Following Renal Transplant
  34. High Rate of Recurrence in Renal Transplant Recipients after a First Episode of Venous Thromboembolism
  35. Nephrotic Syndrome and Renal Failure After Allogeneic Stem Cell Transplantation: Novel Molecular Diagnostic Tools for a Challenging Differential Diagnosis
  36. Enteric-Coated Mycophenolate Sodium (EC-MPS) and Mycophenolate Mofetil (MMF), it is Better to Have the Choice
  37. High CXCL10 Expression in Rejected Kidneys and Predictive Role of Pretransplant Serum CXCL10 for Acute Rejection And Chronic Allograft Nephropathy
  38. Mycophenolate Sodium Delayed Release
  39. Performance of Different Prediction Equations for Estimating Renal Function in Kidney Transplantation
  40. High Pretransplant Serum Levels of CXCL10/IP-10 Are Related to Increased Risk of Renal Allograft Failure
  41. Mycophenolate mofetil versus azathioprine for prevention of acute rejection in renal transplantation (MYSS): a randomised trial
  42. In renal transplantation blood cyclosporine levels soon after surgery act as a major determinant of rejection: Insights from the MY.S.S. Trial
  43. Enteric Coated Mycophenolate Sodium is Therapeutically Equivalent to Mycophenolate Mofetil in de novoRenal Transplant Patients
  44. Changes in viremia and circulating interferon-α during hemodialysis in hepatitis C virus-positive patients: only coincidental phenomena?
  45. Vitamin supplementation reduces the progression of atherosclerosis in hyperhomocysteinemic renal-transplant recipients
  46. A RANDOMIZED, DOUBLE-BLIND TRIAL OF BASILIXIMAB IMMUNOPROPHYLAXIS PLUS TRIPLE THERAPY IN KIDNEY TRANSPLANT RECIPIENTS1,2
  47. HIGH CYSTEINE LEVELS IN RENAL TRANSPLANT RECIPIENTS
  48. HYPERHOMOCYSTEINEMIA IN RENAL TRANSPLANT PATIENTS AS INDEPENDENT CAUSE OF ENDOTHELIAL DAMAGE AND CARDIOVASCULAR DISEASE.
  49. Renoprotective properties of ACE-inhibition in non-diabetic nephropathies with non-nephrotic proteinuria
  50. Persistent parvovirus B19 infections with different clinical outcomes in renal transplant recipients: diagnostic relevance of polymerase chain reaction (PCR) and of quantification of B19 DNA in sera
  51. Functional study of autonomic neuropathy in primary (AL) amyloidosis
  52. Bilateral nephrectomy stopped disease progression in plasma-resistant hemolytic uremic syndrome with neurological signs and coma
  53. Can Plasmapheresis Improve Lupus Nephritis without Its Immunological Markers?